Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATAMS Extension: Atacicept in Relapsing Multiple Sclerosis
NCT00853762Phase 2Terminated
- Sponsor
- EMD Serono
- Start
- Mar 2009
- Primary completion
- Sep 2009
- Modality
- Fc-Fusion Proteins
- Countries
- 17
01
Overview
Phase 2, double-blind trial of atacicept in multiple sclerosis (MS) (4 arms), sponsored by EMD Serono. Primary endpoints: Treatment Emergent Adverse Events at 24 weeks, Vital Signs (BP, Pulse, Temperature) at 36 weeks and 3 more. Started Mar 2009; status: terminated.
02
Drugs
atacicept
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00853762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00853762.